The use of 3D printing technology to create a bionic pancreas, innovative methods of epilepsy diagnosis and treatment as well as neurodevelopmental disorders in children, or new applications of telemedicine in healthcare of patients with heart failure - Polish scientists will be working on these and other innovative technologies and therapies. On 9 May the National Centre for Research and Development (NCBR) settled the third and last competition under the strategic programme "Prevention practices and treatment of civilizational diseases of" - STRATEGMED. Nine science-industry consortia will receive more than PLN 141 million for R&D in the areas of cardiology, neurology, oncology and regenerative medicine.
– The whole world faces common challenges of an aging population, higher incidence of cancer and chronic diseases, and increasing medical costs. To respond to these, it is necessary to invest in new technologies and an effective use of Internet solutions. Thanks to the efforts of Polish scientists and resources available under STRATEGMED, Poland stands a chance not only to be an active participant, but also the creator of the development of global medical progress – said DPM Jarosław Gowin, Minister of Science and Higher Education.
STRATEGMED has been the first strategic R&D programme developed by the NCBR Council on the basis of the National Research Programme. The document had set out R&D directions of strategic importance to the state. It had defined lifestyle diseases as the greatest danger to the health of the Polish population for years to come. The list of lifestyle diseases, included, among others: cardiovascular diseases, malignant cancers and mental illnesses. In view of such challenges, particular emphasis should have been placed on issues related to innovative solutions in prevention, diagnosis and treatment as measures to quickly respond to the challenge of an aging population. STRATEGMED was the answer.
– The implementation of STRATEGMED showed that innovation can have a real impact on improving the quality of life of every Pole. On top of that, innovative medical solutions of our scientists also have a great potential for commercialisation in foreign markets. That is why I believe that projects funded in future competitions will on the one hand provide patients with access to modern diagnostics and therapy, and on the other - contribute to strengthening the competitiveness of the Polish economy and the development of medicine in the world – explains NCBR Director Prof. Maciej Chorowski.
Implemented since 2012, STRATEGMED has consisted of three competitions which resulted in 44 R&D projects funded with a total value of PLN 800 million. With NCBR support, research is being conducted on e.g. innovative vaccine which can reduce the dose of insulin administered to children suffering from Type 1 diabetes, innovative manufacturing technology of laser microprobes used for cancer diagnosis, and on the development of a new therapy of psychotic disorders as well as on Huntington's disease. The programme will last until 2019.
Detailed information can be found on the programme's website.